Canada Markets open in 1 hr 17 mins

Alpha Cognition Inc. (ACOGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.48500.0000 (0.00%)
At close: 02:17PM EDT

Alpha Cognition Inc.

301–1228 Hamilton Street
Vancouver, BC V6B 6L2

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael E. McFaddenCEO & Director429.78kN/A1967
Mr. Kenneth Anthony Cawkell B.A., LL.B.Founder, Special Advisor, Corp. Sec. & Director264.6kN/A1951
Dr. Denis G. Kay Ph.D.Chief Scientific Officer238.57kN/A1957
Ms. Lauren D'Angelo M.B.A.Chief Commercial Officer312.4kN/AN/A
Mr. Donald A. Kalkofen B.A.Chief Financial OfficerN/AN/A1964
Ms. Colleen JohnsSr. VP of Product Devel.N/AN/AN/A
Dr. Cedric O'Gorman M.B.A., M.D., MBAChief Medical OfficerN/AN/A1975
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

Corporate Governance

Alpha Cognition Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.